ALB and myeloid sarcoma: Although it is possible that administration of exogenous albumin or albumin-oleic acid may confer some benefits for MS similar to the preclinical results described above for other conditions, high dose albumin therapy has been tested in clinical trials for ischemic stroke but was found to have no benefit, and it even increased mortality in subjects that were > 83 years old [173].